BAR­DA, Emer­gent BioSo­lu­tions break off $600M Covid-19 vac­cine man­u­fac­tur­ing deal

Af­ter a fi­as­co sur­round­ing the con­t­a­m­i­na­tion of Covid-19 vac­cine dos­es in its fa­cil­i­ties — dur­ing a time in which vac­ci­nat­ing res­i­dents was dire to Amer­i­ca’s re­turn to nor­mal­cy — Emer­gent BioSo­lu­tions’ $600 mil­lion man­u­fac­tur­ing deal with the US gov­ern­ment has come to an end.

CEO Bob Kramer said that the two par­ties “mu­tu­al­ly agreed” to ter­mi­nate the con­tract in an earn­ings call with in­vestors Thurs­day, evap­o­rat­ing about $180 mil­lion in deal val­ue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER